What is Immunic?
Immunic Inc. is a biotherapeutic firm that has focused on developing cell-based therapy approaches for treating acute liver failure. The company's flagship product candidate was the ELAD® System, a bio-artificial liver device designed to enhance survival rates in patients suffering from severe acute liver failure. Immunic has historically dedicated its resources to product development, clinical testing, and pilot manufacturing. However, recent clinical trial outcomes for the ELAD System in severe alcoholic hepatitis did not meet primary endpoints, leading to a strategic shift away from U.S. and European market development for this specific product. This pivot has necessitated a re-evaluation of the company's pipeline and future direction.
How much funding has Immunic raised?
Immunic has raised a total of $63.7M across 3 funding rounds:
Series A
$19.7M
Share Placement
$15M
Debt
$29M
Series A (2016): $19.7M with participation from High-Tech Gru00fcnderfonds, Life Sciences Partners, Bayern Kapital, and LifeCarePartners
Share Placement (2020): $15M led by Altium Capital Limited
Debt (2020): $29M supported by The European Investment Bank
Key Investors in Immunic
Altium Capital Limited
Altium Capital Limited is an investment firm that has participated in Immunic's funding rounds. Further details on their specific investment focus are not publicly available.
Life Sciences Partners
Life Sciences Partners (LSP) is a prominent European venture capital firm specializing in the life sciences sector, investing in innovative companies from early-stage to growth phases.
The European Investment Bank
The European Investment Bank (EIB) is the European Union's long-term lending institution, providing financing for sound investment projects that contribute to the integration, balanced development, and economic cohesion of the EU.
What's next for Immunic?
Following the cessation of ELAD System development for key markets and a substantial workforce reduction, Immunic is actively exploring strategic alternatives. This includes the potential divestiture of company assets and intellectual property. The recent major enterprise-level funding and strategic investment, alongside debt financing from entities like the European Investment Bank, suggest a focus on restructuring and potentially pivoting towards new therapeutic areas or technologies. The company's ability to secure future financing will likely depend on the successful identification and development of new, viable product candidates or strategic partnerships.
See full Immunic company page
